The global prevalence of diabetes is rising and is estimated to reach 8% of the global population by 2030. Approximately 90% of this is estimated to be type 2 diabetes. Most people living with type 2 diabetes have coexisting overweight or obesity, and this is a significant contributor to the worsening diabetes epidemic, yet weight reduction is often not prioritized in treatment plans. Type 2 diabetes and obesity are associated with increased risk for numerous health complications, including cardiovascular disease (CVD), and early mortality. The aim of chronic disease management is to reduce disease burden, improve health and help to ensure a good quality of life for individuals, so why aren’t we doing more?

A recent literature review published in Diabetes Obesity and Metabolism examined the benefits of weight management in people living with type 2 diabetes. The review found that in people with co-existing overweight or obesity, modest and sustained weight reduction is associated with improved glycaemic control and decreased use of glucose-lowering therapies. Total body weight loss of ≥5% reduces HbA1c and improves other risk factors for CVD such as hyperlipidaemia and hypertension, as well improving other comorbid complications of obesity. Moreover, progressive improvements in glycaemic control and cardiometabolic risk factors are seen when total body weight loss increases to ≥10%.